MedTrace Logo

Serum Exosomal miRNA Predicting the Therapeutic Efficiency in Lung Squamous Carcinoma

NCT05854030 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2023-05-11

No results posted yet for this study

Summary

This is an observational prospective bi-center study of 50 patients operated on advanced squamous cell carcinoma. The main aim is to investigate the efficacy of serum exosomal miRNA as a biomarker for predicting the therapeutic effect of immunotherapy combined with chemotherapy.

Conditions

Interventions

DIAGNOSTIC_TEST

collect plasma samples and clinical features

8ml of peripheral blood need to be collected from pre- and post-treatment advanced pulmonary squamous carcinoma separately

Sponsors & Collaborators

  • Tianjin Chest Hospital

    collaborator OTHER

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Principal Investigators

  • Richeng Richeng, Postdoctor · Tianjin Medical University Cancer Institute and Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2023-07-31
Completion
2023-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05854030 on ClinicalTrials.gov